Bicara Therapeutics Ownership | Who Owns Bicara Therapeutics?
Bicara Therapeutics Ownership Summary
Bicara Therapeutics is owned by 101.96% institutional investors, 10.04% insiders. Ra capital management is the largest institutional shareholder, holding 11.95% of BCAX shares. T. Rowe Price US Small-Cap Core Equity is the top mutual fund, with 3.27% of its assets in Bicara Therapeutics shares.
BCAX Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Bicara Therapeutics | 101.96% | 10.04% | -11.99% |
| Sector | Healthcare Stocks | 129.40% | 12.08% | -41.48% |
| Industry | Biotech Stocks | 181.71% | 11.69% | -93.40% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Ra capital management | 7.26M | 11.95% | $215.43M |
| T. rowe price investment management | 6.34M | 10.44% | $188.19M |
| Vestal point capital, lp | 5.25M | 8.65% | $155.87M |
| Siren | 5.50M | 8.10% | $102.41M |
| Deep track capital, lp | 4.10M | 6.75% | $121.73M |
| Janus henderson group | 3.33M | 6.08% | $66.11M |
| Blackrock funding, inc. /de | 3.95M | 5.81% | $73.43M |
| Tpg gp a | 3.01M | 4.96% | $89.38M |
| Red tree management | 2.92M | 4.30% | $54.35M |
| Vanguard group | 2.19M | 4.01% | $36.79M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Red tree management | 2.92M | 46.57% | $54.35M |
| Omega fund management | 1.82M | 29.14% | $54.10M |
| Acorn capital advisors | 643.38K | 5.21% | $19.10M |
| Vestal point capital, lp | 5.25M | 3.64% | $155.87M |
| Aisling capital management lp | 548.92K | 3.41% | $10.22M |
| Jones hill capital lp | 1.06M | 3.36% | $19.81M |
| Superstring capital management lp | 175.90K | 2.74% | $2.78M |
| Siren | 5.50M | 2.42% | $102.41M |
| Palo alto investors lp | 550.41K | 2.26% | $16.34M |
| Ra capital management | 7.26M | 1.87% | $215.43M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Franklin resources | 2.67M | 0.01% | 713.25K |
| Janus henderson group | 3.33M | 0.03% | 680.63K |
| Price t rowe associates inc /md/ | 1.90M | 0.01% | 528.05K |
| Ameriprise financial | 288.75K | 0.00% | 272.93K |
| Schonfeld strategic advisors | 504.08K | 0.05% | 241.33K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Royalty pharma sub-manager | - | - | -2.39M |
| Braidwell lp | - | - | -2.16M |
| Deerfield management company, l.p. (series c) | - | - | -1.80M |
| Citadel advisors | 211.14K | 0.00% | -1.45M |
| Wellington management group llp | - | - | -1.39M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Qube research | 210.93K | 0.00% | 210.93K | $3.93M |
| Cantor fitzgerald, l. p. | 100.00K | 0.01% | 100.00K | $1.58M |
| Quadrature capital | 65.98K | 0.01% | 65.98K | $1.23M |
| Exoduspoint capital management, lp | 53.88K | 0.01% | 53.88K | $850.80K |
| Norges bank | 42.89K | 0.00% | 42.89K | $721.82K |
Sold Out
| Holder | Change |
|---|---|
| Aster capital management (difc) | -1.00 |
| Sbi securities | -1.00 |
| Clearstead advisors | -5.00 |
| Stone house investment management | -11.00 |
| National bank of canada /fi/ | -11.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | 177 | -3.80% | 69,255,507 | -4.55% | 101 | 0.71% | 102 | -10.53% | 39 | - |
| Jun 30, 2026 | 180 | 16.88% | 72,477,808 | 1.71% | 119 | 0.70% | 110 | 22.22% | 39 | -2.50% |
| Mar 31, 2026 | 78 | -45.83% | 15,246,758 | -73.87% | 27 | 0.24% | 48 | -46.67% | 17 | -51.43% |
| Dec 31, 2025 | 92 | -19.30% | 27,836,301 | -44.55% | 51 | 0.60% | 57 | -12.31% | 23 | -14.81% |
| Sep 30, 2025 | 111 | 5.71% | 49,553,927 | -3.15% | 90 | 1.03% | 64 | -18.99% | 26 | 62.50% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| T. Rowe Price US Small-Cap Core Equity | 2.15M | 3.27% | -33.46K |
| Vanguard Total Stock Mkt Idx Inv | 1.68M | 2.55% | 305.30K |
| Vanguard Morn Total Stk Mkt Idx Investor | 1.68M | 2.55% | 305.30K |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.68M | 2.53% | - |
| State Street® SPDR® S&P® Biotech ETF | 1.17M | 1.77% | 30.59K |
| iShares Russell 2000 ETF | 1.11M | 1.68% | - |
| T. Rowe Price U.S. SC Core Eq Tr-D | 1.00M | 1.53% | -29.85K |
| T. Rowe Price Small-Cap Stock | 973.67K | 1.47% | -630.88K |
| Fidelity Select Biotechnology | 902.00K | 1.36% | -42.90K |
| Franklin Biotechnology Discv A(acc)USD | 877.99K | 1.33% | - |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Sep 08, 2026 | Cohlhepp Ryan | President, COO & Interim CEO | Sell | $80.66K |
| Sep 08, 2026 | Cohlhepp Ryan | President, COO & Interim CEO | Sell | $320.05K |
| Aug 10, 2026 | Hyep Ivan | Chief Financial Officer | Sell | $349.59K |
| Aug 10, 2026 | Mazumdar Claire | Chief Executive Officer | Sell | $279.75K |
| Aug 10, 2026 | Cohlhepp Ryan | President and COO | Sell | $524.53K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q3 | - | 14 |
| 2026 Q2 | - | 10 |
| 2026 Q1 | 2 | 21 |
| 2025 Q4 | - | 23 |
| 2025 Q3 | - | 2 |
BCAX Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools